Back to news

Why Novartis (NVS) Stock Is Up Today

Investivoq PriceTracker

Novartis AG (NVS) is up 3.2% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued investor optimism around remibrutinib, which recently won a U.S. label expansion for symptomatic dermographism and already posted positive Phase III data in relapsing multiple sclerosis. The move may also reflect growing confidence that remibrutinib can become a broader growth asset across immunology and neurology ahead of Novartis’s October 23, 2026 investor call on the MS program. ([novartis.com](https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu?utm_source=openai))

Details:

  • On October 7, 2026, Novartis said the FDA approved Rhapsido (remibrutinib) for adults with symptomatic dermographism not adequately controlled by H1 antihistamines, expanding the product beyond chronic spontaneous urticaria. ([novartis.com](https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu?utm_source=openai))
  • The company described the approval as the first treatment for symptomatic dermographism, which can strengthen expectations for a larger commercial runway in immunology. ([novartis.com](https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu?utm_source=openai))
  • Novartis also announced positive Phase III REMODEL-1 and REMODEL-2 results in relapsing multiple sclerosis in September, supporting another potentially meaningful indication for the same medicine. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1114448/000117184326005824/f6k_090126.htm?utm_source=openai))
  • Management has scheduled a remibrutinib-in-MS investor call for October 23, 2026, which may be helping keep attention on the program as investors look toward additional data discussion. ([novartis.com](https://www.novartis.com/investors?utm_source=openai))

    • Sources:

    Novartis, SEC ([novartis.com](https://www.novartis.com/news/media-releases/novartis-rhapsido-remibrutinib-receives-fda-approval-first-treatment-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu?utm_source=openai))

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    EARLY ACCESS
    Receive NVS Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $NVS Hedge Fund Activity

    We have seen 622 institutional investors add shares of $NVS stock to their portfolio, and 668 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • DODGE & COX removed 6,208,010 shares (-89.1%) from their portfolio in Q2 2026, for an estimated $972,919,327
    • GOLDMAN SACHS GROUP INC removed 3,545,603 shares (-54.3%) from their portfolio in Q2 2026, for an estimated $555,666,902
    • JPMORGAN CHASE & CO added 2,264,447 shares (+inf%) to their portfolio in Q2 2026, for an estimated $354,884,133
    • FISHER ASSET MANAGEMENT, LLC added 1,637,629 shares (+11.8%) to their portfolio in Q2 2026, for an estimated $256,649,216
    • HOLOCENE ADVISORS, LP added 1,037,332 shares (+inf%) to their portfolio in Q2 2026, for an estimated $162,570,671
    • PRIMECAP MANAGEMENT CO/CA/ removed 975,230 shares (-12.9%) from their portfolio in Q2 2026, for an estimated $152,838,045
    • MILLENNIUM MANAGEMENT LLC added 758,029 shares (+inf%) to their portfolio in Q2 2026, for an estimated $118,798,304

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $NVS Congressional Stock Trading

    Members of Congress have traded $NVS stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

    Here’s a breakdown of recent trading of $NVS stock by members of Congress over the last 6 months:

    • REPRESENTATIVE KEVIN HERN sold up to $50,000 on 08/27.

    To track congressional stock trading, check out Investivoq's congressional trading dashboard. You can access data on congressional stock trades through the Investivoq API Congress trades endpoint.

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.